ABSTRACT
Top Investigators Explore the Complexities of Angiogenesis Cancer Research
The targeting of tumor angiogenesis has evolved into one of the most widely pursued therapeutic strategies. However, as of yet, no antiangiogenic agent used as a monotherapy has demonstrated a survival benefit in a randomized Phase III trial. The combination of bev
TABLE OF CONTENTS
part |2 pages
Part I Angiogenesis in Cancer
part |2 pages
Part II Targeting Angiogenesis for Cancer Therapy
part |2 pages
Part III Translating Angiogenesis Inhibitors to the Clinic
part |2 pages
Part IV Treatment of Specific Cancers with Angiogenesis Inhibitors
